Tumor necrosis factor is increased in the spinal cord of an animal model of motor neuron degeneration
- PMID: 9681389
Tumor necrosis factor is increased in the spinal cord of an animal model of motor neuron degeneration
Abstract
Autoimmunity and oxidative/excitotoxic damage are considered as possible pathogenetic mechanisms in amyotrophic lateral sclerosis (ALS). As tumor necrosis factor (TNF) is implicated in autoimmune diseases, including experimental autoimmune encephalomyelitis, and can be neurotoxic, we studied TNF production in a proposed animal model of ALS, the mnd mouse. These mice develop symptoms (progressive weakness of the limbs) as late as at 7 months of age. We measured TNF in serum, brain and spinal cord of mnd mice at 3 and 7 months of age. TNF was detectable in the brain and spinal cord (but not in the serum) at 7 months, while no TNF was detected in mnd mice at 3 months (asymptomatic) or in control mice of the same genetic background and the same age. Immunohistochemistry confirmed localization of TNF-alpha in motor neurons situated in the ventral horn of the spinal cord of 7-month old mnd mice. These results suggest the possibility of testing inhibitors of TNF production in this disease.
Similar articles
-
Intraperitoneally administered IgG from patients with amyotrophic lateral sclerosis or from an immune-mediated goat model increase the levels of TNF-α, IL-6, and IL-10 in the spinal cord and serum of mice.J Neuroinflammation. 2016 May 24;13(1):121. doi: 10.1186/s12974-016-0586-7. J Neuroinflammation. 2016. PMID: 27220674 Free PMC article.
-
Increase of glial fibrillary acidic protein fragments in the spinal cord of motor neuron degeneration mutant mouse.Brain Res. 1998 Feb 23;785(1):31-40. doi: 10.1016/s0006-8993(97)00612-4. Brain Res. 1998. PMID: 9526038
-
Mitochondrial oxidative metabolism in motor neuron degeneration (mnd) mouse central nervous system.Eur J Neurosci. 2002 Dec;16(12):2291-6. doi: 10.1046/j.1460-9568.2002.02299.x. Eur J Neurosci. 2002. PMID: 12492423
-
Tumor necrosis factor and motoneuronal degeneration: an open problem.Neuroimmunomodulation. 2001;9(4):178-82. doi: 10.1159/000049024. Neuroimmunomodulation. 2001. PMID: 11847479 Review.
-
Role of complement in motor neuron disease: animal models and therapeutic potential of complement inhibitors.Adv Exp Med Biol. 2008;632:143-58. Adv Exp Med Biol. 2008. PMID: 19025120 Review.
Cited by
-
Tumor Necrosis Factor Alpha in Amyotrophic Lateral Sclerosis: Friend or Foe?Cells. 2021 Mar 1;10(3):518. doi: 10.3390/cells10030518. Cells. 2021. PMID: 33804386 Free PMC article. Review.
-
Intraperitoneally administered IgG from patients with amyotrophic lateral sclerosis or from an immune-mediated goat model increase the levels of TNF-α, IL-6, and IL-10 in the spinal cord and serum of mice.J Neuroinflammation. 2016 May 24;13(1):121. doi: 10.1186/s12974-016-0586-7. J Neuroinflammation. 2016. PMID: 27220674 Free PMC article.
-
Therapeutic Potential of Capsaicin in Various Neurodegenerative Diseases with Special Focus on Nrf2 Signaling.Curr Pharm Biotechnol. 2024;25(13):1693-1707. doi: 10.2174/0113892010277933231122111244. Curr Pharm Biotechnol. 2024. PMID: 38173062 Review.
-
The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment.Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12855-9. doi: 10.1073/pnas.96.22.12855. Proc Natl Acad Sci U S A. 1999. PMID: 10536012 Free PMC article.
-
Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial.Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):393-404. doi: 10.3109/17482960802709416. Amyotroph Lateral Scler. 2009. PMID: 19922130 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous